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ABSTRACT 
The development of wound infection and selection of resistant microorganisms is a sig-
nificant problem in the process of granulation and epithelization of poorly healing leg 
ulcers. In a number of cases, the attempts for systemic treatment with some of the most 
potent antimicrobials, according to the susceptibility data, are unsuccessful. It is estab-
lished that the local application of hyaluronic acid fosters the process of epithelization. In 
a complex with Zinc ions, hyaluronic acid possesses antiseptic effect. The aim of the 
study: To assess the in vitro activity of 0.2% Zinc-hyaluronate solution /Hyaluricht ®/ 
against the most common bacteria isolated from patients with poorly healing leg ulcers. 
Material and methods: A total of ten bacterial strains /Staphylococcus aureus, Pseudo-
monas aeruginosa, Escherichia coli, and Serratia marcescens/ isolated from ten patients 
with long-lasting chronic leg were tested. Antibiotic susceptibility testing was determined 
by standard disk diffusion method. All Escherichia coli and Serratia marcescens strains 
were screened for the production of extended-spectrum β-lactamases by using the double-
disk test. An inoculum suspension from fresh 18-h culture of the tested strains on blood 
agar was prepared in 0.2% Zinc-hyaluronate solution. The time kill experiments were 
performed. Results: Time-kill experiments demonstrated fast bactericidal activity even 
against highly resistant to antimicrobials strains. In our experiments the time for killing 
depended on the species affiliation and the bacterial suspension density. As a conclusion, 
the results confirm the data given in the medical literature for the antimicrobial activity of 
the preparation Hialuricht® and support the approved position in the clinical practice for 
its favorable therapeutic effect in the local treatment of infected ulcers.  
 
Introduction 
The reasons leading to the formation of 
poorly healing leg ulcers are chronic dise-
ases of the arterial and venous systems, as 
well as some connective tissue and auto-
immune diseases (3). The process of hea-
ling of these ulcers is long lasting and 
complicated. Their treatment includes sys-
temic vasoprotective, venous tonic and 
vasodilating remedies, and antibiotics but 
also preparations for local treatment as en-
zymes for cleaning and necrosis removal, 
antimicrobial, epithelizing and protective 
creams and ointments (2, 4). In spite of the 
usage of contemporary non-adherent and 
exudate absorbing polyurethane and hydro-
colloid dressings, surgical treatment of the 
ulcer bottom and edges is often necessary, 
followed by the application of skin auto-
grafts (10). 
The development of wound infection and 
selection of resistant microorganisms 
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(Staphylococcus aureus, Pseudomonas 
aeruginosa and other Gram-negative rods) 
is a significant problem in the process of 
granulation and epithelization. In a number 
of cases, the attempts for systemic treat-
ment according to the susceptibility data 
with some of the most potent antimicrobi-
als are unsuccessful. Because of that, the 
treatment of poorly healing leg ulcers 
caused by resistant microorganisms be-
comes of problem for clinical practice (5). 
The reduced concentration of the natural 
biopolymer hyaluronic acid in the tissues of 
patients with poorly healing leg ulcers ad-
ditionally delays the process of cellular 
proliferation and regeneration. It is estab-
lished that the local application of 
hyaluronic acid fosters the process of epi-
thelization by creating optimal conditions 
for the activation and migration of the cells 
participating in the process of tissue rege-
neration. (9) In a complex with Zinc ions, 
hyaluronic acid possesses antiseptic effect 
(1). Hyaluricht® solution is an original 
preparation of the Hungarian Company 
Gedeon Richter, containing 0.2 % Zinc-
hyaluronate. The aim of this study is to 
assess by time-kill experiments the in vitro 
activity of Hyaluricht® against the most 
common bacteria isolated from patients 
with poorly healing leg ulcers. 
Materials and Methods 
Clinical bacterial strains. A total of ten 
bacterial strains isolated from ten patients 
with long-lasting chronic leg ulcers were 
tested. Eight patients were women and two 
were men, aged 51 to 83 years. Seven of 
them had venous ulcers, two had arterial 
ulcers and one had atonic leg ulcer. Despite 
of long-standing systemic and local treat-
ment all patients had recurrent ulcers of the 
lower limbs. 
The species distribution of the tested 
strains is as follows: Staphylococcus 
aureus (2 strains), Pseudomonas aerugi-
nosa (3 strains), Escherichia coli (2 
strains), and Serratia marcescens (2 
strains). 
Susceptibility testing and antibiotics. 
Antibiotic susceptibility testing was deter-
mined by standard disk diffusion method 
using 10U penicillin, 1μg oxacillin, 10μg 
ampicillin, 20/10 μg amoxicillin/clavulanic 
acid, 75 μg azlocillin, 100 μg piperacillin, 
100/10 μg piperacillin/tazobactam, 30 μg 
cephalothin, 30 μg cefuroxime, 30 μg ce-
fotaxime, 30 μg ceftriaxone, 30 μg ceftaz-
idime, 30 μg cefepime, 10 μg imipenem, 
10 μg meropenem, 30 μg vancomycin, 30 
μg teicoplanin, 10 μg gentamicin, 30 μg 
amikacin, 15 μg erythromycin, 2 μg clin-
damycin, and 5 μg ciprofloxacin. Disks for 
the agar diffusion procedures were ob-
tained from Becton Dickinson Microbio-
logy Systems (Cockeysville, Md.). Break-
points recommended by the NCCLS were 
used to determine susceptibility or resis-
tance (8). 
Test for production of extended-spec-
trum β-lactamases (ESBLs). All E. coli 
and S. marcescens strains were screened 
for the production of ESBLs by using the 
double-disk test (6). A potentiation of the 
zones of cefotaxime, ceftriaxone, ceftaz-
idime, or aztreonam by clavulanic acid re-
presented a positive test result and was in-
dicative of the possible presence of an 
ESBL. 
Time-kill experiments. An inoculum sus-
pension from fresh 18-h culture of the 
tested strains on blood agar was prepared 
in 0.2% hyaluronate solution. The turbidity 
is adjusted to obtain a turbidity optically 
comparable to that of the 0.5 McFarland 
standard. The inoculum suspension was 
incubated at 37 ºC for 24 h. 0.1 ml of the 
undiluted suspension and 10-1, 10-2, 10-3, 
10-4, and 10-5 dilutions were inoculated on 
Mueller-Hinton agar, Becton Dickinson 
Microbiology Systems (Cockeysville, 
Md.), poured in Petri dishes with thickness 
of the agar 5 mm for colony counting. The 
inoculum was performed at the moment of 
preparation of the suspension (0h) and at 
1st hour,   2nd hour,  3rd hour,  4th hour,  5th  
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TABLE 1 
Susceptibility patterns of bacterial strains isolated from poorly healing leg ulcers 
Strain No Species Susceptibility patterns 
1. Staphylococcus aureus (Lab. № 206) PenS OxaS GenS AkS EryS ClinS CipS VanS TeiS 
2. Staphylococcus aureus (Lab. № 306) PenR OxaS GenS AkS EryS ClinS CipS VanS TeiS  
3. Staphylococcus aureus (Lab. № 606) PenS OxaS GenS AkS EryS ClinS CipS VaS TeiS  
4. Pseudomonas aeruginosa (Lab. № 207) AzlS PipS TazS CazR ImpS MerS GenS AkS CipR 
5. Pseudomonas aeruginosa (Lab. № 307) AzlR PipR TazS CazR ImpS MerS GenI AkR CipR 
6. Pseudomonas aeruginosa (Lab. № 604) AzlR PipR TazI CazR ImpI MerI GenR AkR CipR 
7. 
Escherichia coli (Lab. № 158) Ap
R AzlR PipR AmcR CfR CxmR CtxR CroR CazR FepR
ImpS MerS GenR AkR CipR (ESBL+) 
8. 
Escherichia coli (Lab. № 7546) Ap
R AzlR PipR AmcR CfR CxmR CtxR CroR CazR FepR
ImpS MerS GenR AkI CipR (ESBL+) 
9. 
Serratia marcescens (Lab. № 493) Ap
R AzlS AmcR CfR CxmR CtxS CroS CazS FepS ImpS
MerS GenI AkS CipS  
10. 
Serratia marcescens (Lab. № 605) Ap
R AzlS AmcR CfR CxmR CtxS CroS CazS FepS ImpS
MerS GenS AkS CipS  
Legend: S – sensitive, R – resistant, I – intermediate; Pen – penicillin; Oxa – oxacillin; Ap – ampicillin; Amc 
– amoxicillin/clavilanic acid; Azl – azlocillin; Pip – piperacillin; Taz – piperacillin/tazobactam; Cf – 
cephalothin; Cfx – cefuroxime; Ctx – cefotaxime; Cro – ceftriaxone; Caz – ceftazidime; Fep – cefepime; Imp 
– imipenem; Mer – meropenem, Van – vancomycin; Tei – teicoplanin; Gen – gentamicin; Ak – amikacin; Ery 
– erythromycin; Clin – clindamycin; Cip – ciprofloxacin; ESBL+ – producer of β-lactamase with extended 
spectrum 
 
hour, 6th hour, 8th hour, and 24th hour du-
ring the incubation period. The inoculated 
Petri dishes were incubated at 37 ºC for 24 
h. The number of colony forming units 
(CFU) per 1 ml was determined according 
to the formula: 
CFU/ml = the number of colonies x 10 x 
reciprocal value of the dilution. 
All time kill experiments were performed 
in duplicate. Time-kill curves were con-
structed by plotting mean colony counts 
(log10 CFU/ml) versus time (7). 
Results and Discussion 
Table 1 shows susceptibility patterns of the 
tested strains. Two of the three S. aureus 
strains (No 1 and 3) were susceptible to all 
tested antimicrobials and one (No 2) was 
resistant only to penicillin. Both E. coli 
isolates were ESBL-producers and resistant 
to aminopenicillins, ureidopenicillins, 
cephalosporins from 1st – 4th generations, 
aminoglycosides, and fluoroquinolones and 
susceptible only to carbapenems. One 
strain of P. aeruginosa (No 6) was highly 
resistant. It exhibits resistance to ureido-
penicillins, aminoglycosides, and fluoro-
quinolones and intermediate susceptibility 
to carbapenems and piperacil-
lin/tazobactam. The other two P. aerugi-
nosa strains (No 4 and 5) and both S. 
marcescens strains were moderate resistant. 
Killing curves of the tested strains are 
shown on Figures 1 – 4. As it seen from 
the curves, the type of action of 0.2% Zn-
hyaluronate is bactericidal. This action is 
very fast, from 2 to 7 hours, even for 
strains with high resistance to antimicrobi-
als (strains No 6, 7, and 8).  
The data for the time for killing and the 
suspension density are presented in Table 2. 
Differences in the time for killing of the 
separate strains were found. These diffe-
rences are determined to some extent by the  
 

































































































Fig. 4. Time-kill curves of S. marcescens strains treated with 0.2% Zn-hyaluronate. 
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TABLE 2 
Comparative data on the time for killing and the suspension density of microorganisms 
Microbial species Suspension density (CFU/ml) Time for killing the microorganisms 
Strain № 1 Staphylococcus aureus 105 4 hours 
Strain № 7 Escherichia coli 105 2 hours 
Strain № 4 Pseudomonas aeruginosa 106 4 hours 
Strain № 6 Pseudomonas aeruginosa 106 5 hours 
Strain № 2 Staphylococcus aureus 107 5 hours 
Strain № 3 Staphylococcus aureus 107 7 hours 
Strain №5 Pseudomonas aeruginosa 107 4 hours 
Strain № 8 Escherichia coli 107 7 hours 
Strain № 9 Serratia marcescens 107 3 hours 
Strain № 10 Serratia marcescens 107 7 hours 
 
initial density of the bacterial suspension. 
With suspension density 105 CFU/ml, the 
time for killing varies from 2 h to 4 h, with 
density 106 CFU/ml – from 4 h to 5 h and 
with density 107 CFU/ml – from 3 h to >7 
h. The individual peculiarities of the tested 
strains influence the time for killing as 
well. Thus two strains P. aeruginosa with 
density 106 CFU/ml were killed for 2 h and 
4 h, respectively, two strains E. coli with 
density 107 CFU/ml – for 5 h and 7 h, 
respectively and two strains S. marcescens 
with density 107 CFU/ml for 3 h and 7 h, 
respectively.  
In vitro studies of Hyaluricht® antibacte-
rial effect upon the most frequently isolated 
pathogenic microorganisms from patients 
with leg ulcers were carried out (1). The 
results show the most significant effect of 
the preparation against Staphylococcus 
aureus, Pseudomonas aeruginosa and En-
terococcus faecalis. 
In comparison with previous reports, the 
present study found well expressed bacteri-
cidal activity of 0.2% Zn-hyaluronate 
against Staphylococcus aureus, Pseudo-
monas aeruginosa Escherichia coli, and 
Serratia marcescens. Time-kill experi-
ments demonstrated fast bactericidal acti-
vity even against highly resistant to 
antimicrobials strains. In our experiments 
the time for killing depended on the species 
affiliation and the bacterial suspension den-
sity. This may reflects the species specific 
biological characteristics rather than a car-
riage of genes for resistance to antimicro-
bials. 
Conclusions 
As a conclusion, the results from the in 
vitro study of 0.2% Zn-hyaluronate solu-
tion efficiency against the most frequently 
isolated microorganisms from patients with 
Ulcus cruris confirm the data given in the 
medical literature for the antimicrobial ac-
tivity of the preparation Hialuricht® and 
support the approved position in the clini-
cal practice for its favorable therapeutic 
effect in the local treatment of infected ul-
cers (1, 9).  
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